Page 3 - Dupilumab Development Programdupilumab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dupilumab development programdupilumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dupilumab Development Programdupilumab Today - Breaking & Trending Today

Anti-allergy Drug Dupilumab Treats Lung Cancer

Researchers found a pathway linked to allergies that, when blocked, triggers antitumor immunity in lung cancer mouse models. ....

Icahn School Of Medicine At Mount Sinai , Icahn School , Mount Sinai , Lung Cancer , Non Small Cell Lung Cancer , Lung Cancer Treatment , Allergy Drug ,

Data From Phase 3 Trials Demonstrate Efficacy of Dupilumab for Treating COPD, Type 2 Inflammation

Patients with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation had significantly better lung function at least a year into a dupilumab regimen.

....

Ivelin Radkov , Naimish Patel , Georged Yancopoulos , European Medicines Agency , Global Development , Phase 3 Trials , Type 2 Inflammation ,

Gil Yosipovitch, MD: Overview of Current Research on Prurigo Nodularis

During this interview segment, Dr. Yosipovitch discussed his overview of current PN research and a specific study he had presented at EADV.
....

Gil Yosipovitch , Miller School Of Medicine , University Of Miami , European Academy Of Dermatology , Miller School , Prurigo Nodularis ,

Dupilumab Shown to Reduce COPD Exacerbations Substantially in New Phase 3 Data

This data from the NOTUS trial is set to be submitted to the FDA alongside the phase 3 BOREAS trial data later in the year.
....

Georged Yancopoulos , Naimish Patel , Regeneron Pharmaceuticals Inc , Drug Administration , Regeneron Pharmaceuticals , Breakthrough Therapy , Significantly Reduced , Second Positive Phase , Confirming Potential , Become First Approved Biologic , Phase 3 ,

Gil Yosipovitch, MD: New Analysis of Data on Patient Satisfaction with Dupilumab for Prurigo Nodularis

This discussion with Dr. Yosipovitch covered findings presented at EADV 2023 on dupilumab and prurigo nodularis patients’ satisfaction.
....

Gil Yosipovitch , European Academy Of Dermatology , University Of Miami , Miller School Of Medicine , Miller School , Nature Medicine , Prurigo Nodularis ,